SWX:MED

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions for surgical fixation of bone fractures for upper and lower extremities, as well as for the craniomaxillofacial region.


Snowflake Analysis

Excellent balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Medartis Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MED has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

9.4%

MED

1.4%

CH Medical Equipment

1.4%

CH Market


1 Year Return

-24.9%

MED

0.4%

CH Medical Equipment

3.6%

CH Market

Return vs Industry: MED underperformed the Swiss Medical Equipment industry which returned 1.1% over the past year.

Return vs Market: MED underperformed the Swiss Market which returned 3.8% over the past year.


Shareholder returns

MEDIndustryMarket
7 Day9.4%1.4%1.4%
30 Day9.7%17.7%5.4%
90 Day-6.5%-0.6%1.0%
1 Year-24.9%-24.9%0.9%0.4%7.0%3.6%
3 Yearn/a31.2%26.9%20.3%8.0%
5 Yearn/a106.5%93.6%30.8%9.0%

Price Volatility Vs. Market

How volatile is Medartis Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Medartis Holding undervalued compared to its fair value and its price relative to the market?

229.74x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MED's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MED's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MED is poor value based on its PE Ratio (229.7x) compared to the Medical Equipment industry average (41.7x).

PE vs Market: MED is poor value based on its PE Ratio (229.7x) compared to the Swiss market (19.8x).


Price to Earnings Growth Ratio

PEG Ratio: MED is poor value based on its PEG Ratio (6.6x)


Price to Book Ratio

PB vs Industry: MED is good value based on its PB Ratio (2.3x) compared to the CH Medical Equipment industry average (5.4x).


Next Steps

Future Growth

How is Medartis Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

35.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MED's forecast earnings growth (35% per year) is above the savings rate (-0.2%).

Earnings vs Market: MED's earnings (35% per year) are forecast to grow faster than the Swiss market (8.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MED's revenue (8% per year) is forecast to grow faster than the Swiss market (2.4% per year).

High Growth Revenue: MED's revenue (8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MED's Return on Equity is forecast to be low in 3 years time (0.9%).


Next Steps

Past Performance

How has Medartis Holding performed over the past 5 years?

-22.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MED has high quality earnings.

Growing Profit Margin: MED's current net profit margins (1.6%) are lower than last year (3.5%).


Past Earnings Growth Analysis

Earnings Trend: MED's earnings have declined by -22% per year over the past 5 years.

Accelerating Growth: MED's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MED had negative earnings growth (-48.9%) over the past year, making it difficult to compare to the Medical Equipment industry average (-13.5%).


Return on Equity

High ROE: MED's Return on Equity (1%) is considered low.


Next Steps

Financial Health

How is Medartis Holding's financial position?


Financial Position Analysis

Short Term Liabilities: MED's short term assets (CHF180.9M) exceed its short term liabilities (CHF30.1M).

Long Term Liabilities: MED's short term assets (CHF180.9M) exceed its long term liabilities (CHF42.8M).


Debt to Equity History and Analysis

Debt Level: MED's debt to equity ratio (0.01%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if MED's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: MED's debt is well covered by operating cash flow (26059.1%).

Interest Coverage: MED's interest payments on its debt are well covered by EBIT (11.5x coverage).


Balance Sheet


Next Steps

Dividend

What is Medartis Holding's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MED's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MED's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MED's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Christoph Brönnimann (53yo)

0.75

Tenure

Mr. Christoph Brönnimann has been Chief Executive Officer and Member of Executive Management Board of Medartis Holding AG since September 1, 2019 and has responsibility for the sales organisation since Nov ...


Leadership Team

NamePositionTenureCompensationOwnership
Christoph Brönnimann
CEO & Member of Executive Management Board0.75yrno data0.013% CHF63.0k
Dominique Leutwyler
CFO, Deputy CEO & Member of Executive Management Board19.42yrsno data0.13% CHF618.6k
Axel Maltzen
Chief Production Officer & Member of Executive Management Board6yrsno data0.024% CHF117.6k
Thomas Tribelhorn
CTO & Member of Executive Management Board7.67yrsno data0.032% CHF158.5k
Anthony Durieux-Menage
Chief Human Resources Officer & Member of the Executive Management Board1.42yrsno datano data
Lisa Thompson
President of North America & Member of Executive Management Board0.17yrno datano data
Patrick Christ
Head of Corporate Servicesno datano datano data

3.7yrs

Average Tenure

49yo

Average Age

Experienced Management: MED's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Damien Tappy
Director2.42yrsCHF195.71k0.11% CHF543.0k
Dominik Ellenrieder
Vice-Chairman18.42yrsCHF215.03kno data
H. C. Straumann
Chairman23.42yrsCHF581.99k47.77% CHF236.3m
Marco Gadola
Independent Director0.17yrno datano data
Roland Hess
Director3.42yrsCHF224.99k0.077% CHF382.8k
Willi Miesch
Director10.42yrsCHF1.36m6.02% CHF29.8m
Jürg Greuter
Director23.42yrsCHF109.42k0.022% CHF109.4k
Daniel Herren
Director3.42yrsCHF113.15k0.019% CHF93.0k

6.9yrs

Average Tenure

56.5yo

Average Age

Experienced Board: MED's board of directors are considered experienced (6.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medartis Holding AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medartis Holding AG
  • Ticker: MED
  • Exchange: SWX
  • Founded: 1997
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: CHF494.682m
  • Shares outstanding: 11.78m
  • Website: https://www.medartis.com

Number of Employees


Location

  • Medartis Holding AG
  • Hochbergerstrasse 60E
  • Basel
  • Basel-Stadt
  • 4057
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MEDSWX (SIX Swiss Exchange)YesRegister SharesCHCHFMar 2018

Biography

Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions for surgical fixation of bone fractures for upper and lower extremities, as well as for the craniomaxillofacial region. The company offers plates and screws solutions to treat various fractures, osteotomies, and degenerative diseases of hand, wrist, elbow, shoulder, and foot and ankle under the APTUS name; and implants for fracture fixations and osteotomies in the mandibular, and midface and cranial regions under the MODUS name. Medartis Holding AG’s products also used in tumor reconstruction and orthognathic deformities of the skull. The company sells its products through a network of direct sales representatives primarily to surgeons, hospitals, and medical centers, as well as to group purchasing organizations worldwide. Medartis Holding AG was founded in 1997 and is headquartered in Basel, Switzerland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/04 10:24
End of Day Share Price2020/06/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.